---
document_datetime: 2025-11-23 07:04:11
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/primavax.html
document_name: primavax.html
version: success
processing_time: 0.0481416
conversion_datetime: 2025-12-24 00:01:20.876232
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Primavax

[RSS](/en/individual-human-medicine.xml/67122)

##### Withdrawn

This medicine's authorisation has been withdrawn

diphtheria, tetanus and hepatitis B (rDNA) vaccine (adsorbed)

Medicine

Human

Withdrawn

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

On 5 February 1998, the European Commission issued a Marketing Authorisation valid throughout the European Union for the medicinal product Primavax, which is a combined trivalent vaccine. The pharmaceutical company responsible for this medicinal product is Aventis Pasteur MSD S.N.C.

On 18 May 2000, the Marketing Authorisation holder notified the European Commission about the Marketing Authorisation holder's decision to withdraw the Marketing Authorisation for Primavax.

On 27 July 2000, the European Commission adopted the decision, withdrawing the Marketing Authorisation for the medicinal product for human use \"Primavax - Diphtheria, Tetanus and Hepatitis B vaccine\" EU/1/97/056/001. Pursuant to this decision the European Public Assessment Report for Primavax has been removed from this website.

## Product information

27/07/2000

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

## Product details

Name of medicine Primavax Active substance

- Diphtheria toxoid
- hepatitis B, recombinant surface antigen
- tetanus toxoid

International non-proprietary name (INN) or common name diphtheria, tetanus and hepatitis B (rDNA) vaccine (adsorbed) Therapeutic area (MeSH)

- Hepatitis B
- Tetanus
- Immunization
- Diphtheria

Anatomical therapeutic chemical (ATC) code J07CA

### Pharmacotherapeutic group

Vaccines

### Therapeutic indication

This vaccine is indicated for active immunization against hepatitis B, caused by all known subtypes, diphtheria and tetanus in infants :

## Authorisation details

EMA product number EMEA/H/C/000156 Marketing authorisation holder

Pasteur Mà¨rieux MSD

PASTEUR MERIEUX - MSD 8, rue Jonas SALK 69367 LYON Cà©dex 07 France

Marketing authorisation issued 05/02/1998 Withdrawal of marketing authorisation 27/07/2000

**This page was last updated on** 04/12/2000

## Share this page

[Back to top](#main-content)